|Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.|
|PMID: 20216409 Owner: NLM Status: MEDLINE|
|OBJECTIVES: The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations.
METHODS: The pharmacokinetics (plasma concentrations of l-dopa and 3-O-methyldopa [3-OMD]) and motor effects (global score of the Unified Parkinson's Disease Rating Scale-III) of a single dose of l-dopa (plus the peripheral decarboxylase inhibitor 1:4) were determined in 14 patients with advanced PD. Patients were classified into 2 groups according to Hoehn and Yahr scale (stages 2 and 3). In 1 patient with severe dyskinesias and fluctuations, pk/pd of l-dopa were evaluated before and after coadministration of tolcapone at 100 mg 2 times daily for 1 month. The pk/pd analysis was based on an estimate of the maximal response model with a semiparametric approach to effect site equilibrium.
RESULTS: The highest levels of l-dopa and 3-OMD were observed in patients with stage 3 of Hoehn and Yahr scale. We showed differences in the pk/pd parameters after coadministration of tolcapone in 1 patient as well as the clinical improvement.Univariate analysis showed some significant correlations (P < 0.05) between l-dopa pk/pd parameters and patients' age, duration of l-dopa treatment, and duration of the disease. Multivariate analysis adjusted for patients' age, sex, duration of the disease, and Hoehn and Yahr stage showed that presence of diphasic (dyskinesia-improvement-dyskinesia [DID]) dyskinesias was the only independent predictor of larger threshold level - EC50 (mean concentration at half maximal effect) of l-dopa (P = 0.034).
CONCLUSIONS: The motor complications during long treatment therapy in patients with advanced PD especially with stage 3 Hoehn and Yahr scale were correlated to the higher plasma concentrations of l-dopa. In the presented study, patients with motor complications, especially with DID dyskinesias, exhibited a larger threshold level (EC50). The clinical improvement of a patient who received l-dopa and tolcapone can be explained by tolcapone-induced changes of peripheral and central l-dopa pharmacokinetics, which led to a decrease of l-dopa EC50 and 3-OMD concentrations. Our data indicate that pk/pd analysis may be helpful for monitoring the efficiency of therapeutic strategy applied in PD patients.
|Urszula Adamiak; Maria Kaldonska; Gabriela Klodowska-Duda; Elzbieta Wyska; Krzysztof Safranow; Monika Bialecka; Barbara Gawronska-Szklarz|
Related Documents :
|17442759 - Cognitive impairment in parkinson's disease.
21832229 - Immune reconstitution inflammatory syndrome in natalizumab-associated pml.
7600189 - Olfactory testing as an aid in the diagnosis of parkinson's disease: development of opt...
17326839 - Prediction of outcome in adults with severe falciparum malaria: a new scoring system.
18591079 - The tropicamide eye drop test in parkinson's disease.
17987649 - Factors predicting response to dopaminergic treatment for resting tremor of parkinson's...
3618109 - Csf hydrodynamics after subarachnoid hemorrhage.
698389 - Monoclonal igg anticoagulants delaying fibrin aggregation in two patients with systemic...
12625599 - C-reactive protein and rapidly progressive coronary artery disease--is there any relation?
|Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural|
|Title: Clinical neuropharmacology Volume: 33 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2010 May|
|Created Date: 2010-05-26 Completed Date: 2010-08-31 Revised Date: 2013-11-25|
Medline Journal Info:
|Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States|
|Languages: eng Pagination: 135-41 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Age of Onset
Antiparkinson Agents / adverse effects, pharmacokinetics*, pharmacology*, therapeutic use
Benserazide / adverse effects, pharmacology, therapeutic use
Benzophenones / pharmacology, therapeutic use
Carbidopa / adverse effects, pharmacology, therapeutic use
Catechol O-Methyltransferase / antagonists & inhibitors
Dopa Decarboxylase / antagonists & inhibitors
Drug Therapy, Combination
Dyskinesias / drug therapy
Enzyme Inhibitors / adverse effects, pharmacology, therapeutic use
Levodopa / adverse effects, pharmacokinetics*, pharmacology*, therapeutic use
Metabolic Clearance Rate / drug effects
Nitrophenols / pharmacology, therapeutic use
Parkinson Disease / drug therapy, metabolism*, physiopathology
Severity of Illness Index
Tyrosine / analogs & derivatives, blood
|0/Antiparkinson Agents; 0/Benzophenones; 0/Drug Combinations; 0/Enzyme Inhibitors; 0/Nitrophenols; 0/benserazide, levodopa drug combination; 0/carbidopa, levodopa drug combination; 42HK56048U/Tyrosine; 46627O600J/Levodopa; 762OS3ZEJU/Benserazide; CIF6334OLY/tolcapone; EC 126.96.36.199/Catechol O-Methyltransferase; EC 4.1.1.-/Dopa Decarboxylase; MNX7R8C5VO/Carbidopa; V3O7J20DWN/3-methoxytyrosine|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the ...
Next Document: The interaction between adipokines, diet and exercise on muscle insulin sensitivity.